STOCK TITAN

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced participation in the Piper Sandler Virtual 32nd Annual Healthcare Conference from December 1-3, 2020. The management team will engage in a fireside chat and hold one-on-one investor meetings on December 2, 2020. A webcast of the chat will be available on the Company's website, with a replay accessible for 30 days post-event. Aquestive focuses on developing differentiated pharmaceutical products addressing unmet patient needs, with a pipeline targeting CNS diseases and innovative drug delivery technologies like PharmFilm®.

Positive
  • None.
Negative
  • None.

WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.

A webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

Investor inquiries:
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282

 


FAQ

What is the date of the Piper Sandler Virtual Healthcare Conference for AQST?

The Piper Sandler Virtual 32nd Annual Healthcare Conference will be held from December 1-3, 2020.

When will the fireside chat for AQST take place?

The fireside chat will take place during the conference on December 2, 2020.

How can investors access the AQST fireside chat?

Investors can access the fireside chat via a webcast available on the 'Events and Presentation' page of the Investors section of the Company’s website.

What is the focus of Aquestive Therapeutics?

Aquestive Therapeutics focuses on developing innovative pharmaceutical products to address unmet patient needs, particularly in the central nervous system.

What technology does Aquestive use in its drug development?

Aquestive utilizes proprietary technologies like PharmFilm® for the development of complex orally administered drug molecules.

Aquestive Therapeutics, Inc.

NASDAQ:AQST

AQST Rankings

AQST Latest News

AQST Stock Data

331.89M
86.22M
5.01%
56.03%
10.93%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WARREN